DE LERMA BARBARO, ANDREA
 Distribuzione geografica
Continente #
EU - Europa 4.399
NA - Nord America 4.295
AS - Asia 897
Continente sconosciuto - Info sul continente non disponibili 5
OC - Oceania 2
SA - Sud America 1
Totale 9.599
Nazione #
US - Stati Uniti d'America 4.192
IT - Italia 2.272
UA - Ucraina 874
TR - Turchia 350
SE - Svezia 344
VN - Vietnam 308
FI - Finlandia 227
CN - Cina 211
IE - Irlanda 208
DE - Germania 203
CA - Canada 102
GB - Regno Unito 97
FR - Francia 92
BE - Belgio 49
IN - India 21
RU - Federazione Russa 9
NL - Olanda 8
CH - Svizzera 5
EU - Europa 5
JP - Giappone 5
AT - Austria 3
ES - Italia 2
NZ - Nuova Zelanda 2
RS - Serbia 2
AZ - Azerbaigian 1
CO - Colombia 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
GL - Groenlandia 1
GR - Grecia 1
PL - Polonia 1
TW - Taiwan 1
Totale 9.599
Città #
Milan 1.662
Jacksonville 663
Chandler 485
Fairfield 420
Woodbridge 339
Wilmington 243
Ashburn 240
Princeton 225
Izmir 215
Dublin 208
Nyköping 205
Ann Arbor 193
Dearborn 182
Seattle 172
Houston 161
Dong Ket 143
Cambridge 124
Rome 112
Como 97
Toronto 93
Beijing 85
San Mateo 83
New York 52
San Diego 52
Brussels 49
Düsseldorf 28
Verona 22
Pune 21
Hefei 18
London 15
Nanjing 15
Boardman 14
Helsinki 12
Guangzhou 10
Kunming 9
Jinan 8
Norwalk 8
Redwood City 8
Ponte Lambro 7
Washington 7
Hanover 6
Hounslow 6
Rozzano 6
Villanova D'asti 6
Auburn Hills 5
Falls Church 5
Fuzhou 5
Los Angeles 5
Vanzaghello 5
Zhengzhou 5
Casorezzo 4
Hebei 4
Prescot 4
Seveso 4
Voghera 4
Xian 4
Changsha 3
Chiswick 3
Costa Mesa 3
Edinburgh 3
Huzhou 3
Indiana 3
Nanchang 3
Ottawa 3
Phoenix 3
San Francisco 3
Shenyang 3
Tokyo 3
Varese 3
Wenzhou 3
Zurich 3
Acton 2
Amsterdam 2
Belgrade 2
Boydton 2
Chengdu 2
Chongqing 2
Frankfurt am Main 2
Graz 2
Monza 2
Muggiò 2
Philadelphia 2
Quzhou 2
Redmond 2
Rudolfstetten 2
Simi Valley 2
Wandsworth 2
Wuhan 2
Ürümqi 2
Atlanta 1
Auckland 1
Baku 1
Baotou 1
Biella 1
Birmingham 1
Bogotá 1
Büdelsdorf 1
Cardano 1
Chaoyang 1
Chicago 1
Totale 6.875
Nome #
Surface protein components from entomopathogenic nematodes and their symbiotic bacteria: effects on immune responses of the greater wax moth, Galleria mellonella (Lepidoptera: Pyralidae) 164
Divergent evolution in the mechanisms controlling major histocompatibility complex class II gene transcription in mouse and human 158
CIITA-driven MHC-II positive tumor cells: preventive vaccines and superior generators of antitumor CD4(+) T lymphocytes for immunotherapy 155
The MHC class II transactivator: prey and hunter in infectious diseases 154
New strategies of mammary cancer vaccination 147
Active suppression of the class II transactivator-encoding AIR-1 locus is responsible for the lack of major histocompatibility complex class II gene expression observed during differentiation from B cells to plasma cells 141
CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection and specific anti-tumor memory. 140
CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific anti-tumor memory 133
Inflammatory cues acting on the adult intestinal stem cells and the early onset of cancer (Review) 130
The HLA class II transcriptional activator blocks the function of HIV-1 Tat and inhibits viral replication 130
Distinct regulation of HLA class II and class I cell surface expression in THP-1 macrophage cell line after bacterial phagocytosis 128
MHC class II gene regulation: some historical considerations on a still ontogenetic and phylogenetic puzzle 128
Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent antitumor preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions. 127
The MHC class II transcriptional activator (CIITA) inhibits HTLV-2 viral replication by blocking the function of the viral transactivator Tax-2 121
In Vivo Effects of A Pro-PO System Inhibitor on the Phagocytosis of Xenorhabdus Nematophila in Galleria Mellonella Larvae 120
Highly stable oligomerization forms of HIV-1 Tat detected by monoclonal antibodies and requirement of monomeric forms for the transactivating function on the HIV-1 LTR 119
CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a TH1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory 117
Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent antitumor preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions 111
CIITA-driven MHC-II positive tumor cells: preventive vaccines and superior generators of antitumor CD4+ T lymphocytes for immunotherapy 109
HIV-1 Tat mutants in the cysteine-rich region down-regulate HLA class II expression in T lymphocytic and macrophage cell lines 108
Transient internalization and/or block of export to the cell surface of HLA Class II and CD1b molecules after bacterial phagocytosis 105
Evidence for a specific post-transcriptional mechanism controlling the expression of HLA-DQ, but not -DR and -DP, molecules 104
MHC immunoevasins: protecting the pathogen reservoir in infection 103
Antitumor vaccines and immunotherapeutic strategies based on CIITA-driven MHC class II espression in cancer cells. 101
PHYSIOLOGICAL TARGET OF THE AIR-1 TRANSACTIVATOR REVEALED BY STABLE TRANSFECTION ASSAY 100
Inflammation, inflammatory cells and angiogenesis: decisions and indecisions 99
The complex liaison between cachexia and tumor burden 99
Tumor treatment by TNF-alpha targeted to tumor vessels and melphalan induces strong adaptive immune response, protection from tumor growth and anti-tumor memory. 97
Induction of CIITA and modification of in vivo HLA-DR promoter occupancy in normal thymic epithelial cells treated with IFN-gamma: similarities and distinctions with respect to HLA-DR-constitutive B cells 97
A new strategy of tumor vaccination based on mammary adenocarcinoma cells transduced with the MHC class II transactivator CIITA 96
Transient internalization and/or block of export to the cell surface of HLA Class II and CD1B molecules after mycobacterial phagocytosis 96
The MHC class II transactivator (CIITA): a "physiologic" drug against HIV-1 replication 91
Apoptotic DNA binds to HLA class II molecules inhibiting antigen presentation and partecipatine in the development of anti-inflammatory functional behavior of phagocytic macrophages 90
Therapy-induced antitumor vaccination by targeting TNFa to tumor vessels in combination with melphalan 90
Evidence for a specific post- transcriptional mechanism controlling the expression of HLA-DQ, but not DR and DP molecules 90
TPA-mediated down-regulation of MHC class II gene expression in human macrophage precursors by destabilization of the MHC-II transactivator (CIITA) mRNA 89
Experimental therapeutic approaches to adenocarcinoma: the potential of tumor cells engineered to express MHC class-II molecules combined with naked DNA interleukin-12 gene transfer 88
CIITA-driven MHC-II+ tumor cells: preventive vaccines and superior generators of anti-tumor CD4+ T lymphocytes for immunotherapy. 87
Efficient antigen presentation and T cell activation by MHC class II molecules of CIITA-transfected epatocarcinoma cells 86
The MHC class II transactivator, CIITA, blocks the transcriptional activity of both HTLV-2 Tax-2 and HTLV-1 Tax-1 85
Irradiated CIITA-positive mammary adenocarcinoma cells act as potent anti-tumor preventive vaccine by inducine tumor-specific CD4+ T cell priming and CD8+ T cell effector functions 85
The utility of introducing a measurement of tumor burden for a better assessment of cancer cachexia. 85
CIITA reduced transcription as the cause of HLA class II downregulation in human macrophages during bacterial phagocytosis 84
Tumor rejection and anti-tumor memory to cancer cells of different histotype genetically modified to express CIITA-driven autologous MHC class II genes. A new strategy of anti-tumor vaccination and tumor immunotherapy. 84
Regulation of HLA antigen expression in HIV infected cells 84
CIITA-driven MHC class II expressing tumor cells of distinct hystotype act as a potent antitumor vaccine and as a superior generators of tumor-specific CD4+ T lymphocytes for immunotherapy. 83
Analysis of microchimerism in thyroid autoimmune diseases 83
The complex liaison between vulnerability to cachexia and tumor burden. 83
Reduced expression of the AIR-1 gene product CIITA as the cause of HLA class II down-modulation in normal human macrophages during bacterial phagocytosis 82
HLA class II expression in uninducible hepatocarcinoma cells after transfection of AIR-1 gene product CIITA. Acquisition of antigen processing and presentation capacity. 82
Espressione delle molecole HLA di classe II in cellule di epatocarcinoma classe II negative dopo trasfezione del transattivatore CIITA. Acquisizione della capacità di processare e presentare l'antigene 82
The HLA class II transcriptional activator (CIITA) blocks the function of HIV-1 Tat and inhibits viral replication 82
Block of Stat-1 activation in macrophages, undergoing bacterial phagocytosis causes CIITA reduced transcription and consequent impaired antigen presentation 81
Therapy-induced antitumor vaccination by targeting tumor necrosis factor alpha to tumor vessels in combination with melphalan 81
CIITA blocks the function of HIV-1 Tat by competing for cyclin T1 and inhibits viral replication 81
CIITA reduced transcription as the cause of HLA class II down-modulation in human macrophages during bacterial phagocytosis 81
La presentazione antigenica su molecole di II classe HLA è profondamente alterata in seguito a fagocitosi batterica 80
The MHC class II transactivator (CIITA): a physiologic inhibitor of HIV1 and HTLV2 retroviral infections 80
The molecular basis of the inhibition of HTLV-2 retroviral replication by the MHC class II transactivator (CIITA) 79
Induction of tumor regression by gene transfer of the MHC class II transactivator CIITA 78
Regolazione dell'espressione dei geni del Complesso Maggiore di Istocompatibilità HLA e di CD4 in cellule infettate da HIV: effetto di TAT 78
Higly stable oligomerization forms of HIV-1 Tat detected by Monoclonal antibodies and requirement of monomeric forms for the transactivating function of the HIV-1 LTR 77
Imaging guided percutaneous microwave ablation of tumors. 77
Methylation of CIITA promoter IV causes loss of HLA-II inducibility by gamma-IFN in promyelocytic cells 76
Regulation of HLA antigen expression in phagocytes with mycobacteria 76
The MHC class II transactivator (CIITA): a physiologic inhibitor of HTLV-2 retroviral infection. 76
Analysis of a combined immunodeficiency patient with defect in MHCII expression (BLS) reveals the presence of several mutant isoforms of RFXANK mRNA 76
HTLV2 influence on pathways regulating proliferation and death in B cell line BJAB 75
Reduced expression of the AIR-1 gene product CIITA as the cause of HLA class II down modulation in normal human macrophages during bacterial phagocytosis. 75
HLA-DQ expression is differently regulated from -DR and -DP 73
The HLA class II transcriptional activator (CIITA) blocks the function of HIV-1 Tat and inhibits viral replication 73
The molecular and cellular basis of tumor rejection after vaccination with mammary adenocarcinoma cells transduced with the MHC class II transactivator CIITA 73
Control of tumor growth in vivo by gene therapy with the MHC class II transactivator (CIITA) 73
Tumor vaccination by CIITA-mediated MHC-II-expressing neoplastic cells 72
Irradiated CIITA-positive mammary adenocarcinoma cells act as effective tumor cell vaccine inducing both tumor-specific CD4+ and CD8+ T immune responses and tumor rejection upon challenge. 71
The MHC class II transactivator is a strong physiologic antagonist of HIV-1 replication 70
Temporal and quantitative relations between CIITA and HLA class II expression 69
The replication of HTLV-2 and the expression of HLA class II transcriptional activator (CIITA) are inversely correlated 69
Control of tumor growth in vivo by gene therapy with the MHC class II transactivator CIITA 69
Regulation of HLA antigen expression in phagocytes treated with mycobacteria 69
HLA class II-dependent antigen presentation is deeply impaired in macrophage reservoir of infection 68
Strong adaptive antitumor immune response elicited by targeting tumor necrosis factor a to tumor vessels in combination with melphalan. 68
The MHC class II transactivator (CIITA) mRNA stability is critical for the HLA class II gene expression in differentiating myelomonocytic cells. 67
Inhibition of human T cell leukemia virus type 2 (HTLV-2) replication by the suppressive action of class II transactivator and nuclear factor Y 67
Inibizione della replicazione virale di HIV-1 e HTLV-2 da parte di CIITA il regolatore trascrizionale dell'espressione dell'HLA-II 67
Reverse correlation between HTLV-II replication and expression of CIITA, the major regulator of HLA class II transcription 66
Constitutive and inducible expression of HLA class II genes in normal cells is under the control of the AIR-1-encoded CIITA trans-activator 65
Innate and adaptive immune function of the MHC class II transactivator, CIITA, against human tumor retroviruses HTLV-2 and HTLV-1 64
The immunological basis of tumor rejection and anti-tumor memory to neoplasias of different histotype genetically modified to express CIITA-driven autologous MHC class II genes. 63
Reverse correlation between HTLV-II replication and expression of CIITA, the major regulator of HLA class II transcription 63
Protection from tumor growth and long-lasting anti-tumor immune memory induced by genetically modified mammary adenocarcinoma cells expressing the MHC class II transactivator CIITA 63
Induction of tumor rejection by gene transfer of the MHC class II transactivator CIITA 63
Characterization of an epigenetic variant lacking MHC-II inducibility by IFN-g in the promyelocytic cell line THP-1 62
A new strategy of tumor vaccination based on tumor cells transduced with the MHC class II transactivator CIITA 62
La fagocitosi di Mycobacterium Tuberculosis ha effetti opposti sull'espressione di superficie delle molecole HLA di classe I e di classe II 62
Expression of AIR-1/CIITA transactivator in B cell x plasmacytoma somatic cell hybrids restores HLA-DR and -DP expression, but not -DQ 62
Gene transfer of the MHC-II transactivator CIITA in a murine adenocarcinoma results in immune-mediated tumor rejection 62
Non-replicating MHC Class II- CIITA-positive mammary adenocarcinoma cells act as an effective anti-tumor-preventive vaccine by inducing long-lasting tumor-specific CD8+ T cells and potent CD4+ T helper cells. 61
The immunological basis of therapy-induced antitumor vaccination by targeting Tumor Necrosis Factor a to tumor vessels in combination with melphalan 61
Control of tumor growth in vivo by gene therapy with the MHC class II transactivator CIITA 60
Totale 8.916
Categoria #
all - tutte 28.482
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.482


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019598 0 0 0 0 0 0 0 112 7 52 132 295
2019/20201.495 49 35 54 253 65 165 243 219 91 172 14 135
2020/20211.339 14 136 8 138 24 147 44 130 244 55 128 271
2021/20221.033 134 125 97 109 22 17 41 90 50 114 87 147
2022/20231.340 139 61 115 156 89 297 10 181 158 50 48 36
2023/20242.463 411 412 465 458 469 204 23 21 0 0 0 0
Totale 9.646